Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Henri Roche

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Dermatology (Basel, Switzerland)|October 1, 2015
Chemotherapy-Related Reticulate Hyperpigmentation: A Case Series and Review of the LiteratureMarie Masson Regnault, Noémie Gadaud, Serge Boulinguez, et al.
Trials|July 24, 2013
A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trialJosé Baselga, Frederico Costa, Henry Gomez, et al.
Cancer|May 21, 2011
Q-TWiST analysis of ixabepilone in combination with capecitabine on quality of life in patients with metastatic breast cancerPatricia K Corey-Lisle, Ronald Peck, Pralay Mukhopadhyay, et al.
European Journal of Dermatology : EJD|August 24, 2016
Dermatological adverse events with taxane chemotherapyVincent Sibaud, Nicole R Lebœuf, Henri Roche, et al.
Breast Cancer Research : BCR|November 3, 2011
Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomized trialJocelyne Jacquemier, Jean-Marie Boher, Henri Roche, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2010
Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimensVicente Valero, John Forbes, Mark D Pegram, et al.
Breast Cancer Research and Treatment|June 30, 2010
Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancerFrançois Bertucci, Nathalie Borie, Henri Roche, et al.
The Lancet. Oncology|March 25, 2011
Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled studyMiguel Martin, Henri Roche, Tamas Pinter, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Dermatology (Basel, Switzerland)|October 1, 2015
Chemotherapy-Related Reticulate Hyperpigmentation: A Case Series and Review of the LiteratureMarie Masson Regnault, Noémie Gadaud, Serge Boulinguez, et al.
Trials|July 24, 2013
A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trialJosé Baselga, Frederico Costa, Henry Gomez, et al.
Cancer|May 21, 2011
Q-TWiST analysis of ixabepilone in combination with capecitabine on quality of life in patients with metastatic breast cancerPatricia K Corey-Lisle, Ronald Peck, Pralay Mukhopadhyay, et al.
European Journal of Dermatology : EJD|August 24, 2016
Dermatological adverse events with taxane chemotherapyVincent Sibaud, Nicole R Lebœuf, Henri Roche, et al.
Breast Cancer Research : BCR|November 3, 2011
Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomized trialJocelyne Jacquemier, Jean-Marie Boher, Henri Roche, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2010
Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimensVicente Valero, John Forbes, Mark D Pegram, et al.
Breast Cancer Research and Treatment|June 30, 2010
Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancerFrançois Bertucci, Nathalie Borie, Henri Roche, et al.
The Lancet. Oncology|March 25, 2011
Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled studyMiguel Martin, Henri Roche, Tamas Pinter, et al.
Pageof 2